Future therapies for Parkinson's disease.
Hauser
Robert A
RA
Department of Neurology, University of South Florida and Tampa General Healthcare, Tampa, FL 33606, USA. rhauser@hsc.usf.edu
Lyons
Kelly E
KE
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000639:trends; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005544:Forecasting; D015316:Genetic Therapy / Q000639:trends; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D009414:Nerve Growth Factors / Q000009:adverse effects / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D008996:Monoamine Oxidase Inhibitors; D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D007980:Levodopa